Ofcourse he would never admit that they are going to get bought. It has always been NWBO's official policy that they are going to bring DCVAXL to market until of course they get an offer they cant refuse. This is common practice with every nonrevenue biotech they are going after it alone until they are being bought. As if NWBO would shout from the roves that they are for sale. Also, bringing DCVAXL for GBM to the market would cost hundreds of millions which they dont have even after FDA approval. His notion that they have an "excellent" infrastructure to sell DCVAXL L is laughable they don't have that.
They will be bought after FDA approval.
What is interesting is that they are now double-checking everything before submitting phase. I expect the MAA to be submitted with the MHRA this month and accepted half of August.
Market Data 
Markets 
AI
